Core Viewpoint - The article discusses the recent progress of Hangzhou Deshi Biotechnology Co., Ltd. in its IPO application process in Hong Kong, positioning itself as a potential leader in the medical imaging AI sector, specifically aiming to become the first company in this field to go public [2]. Company Overview: Focused on Medical Imaging AI - Deshi Biotechnology, established in 2018 and headquartered in Hangzhou, specializes in medical imaging artificial intelligence and intelligent diagnostic software, with core technologies covering imaging algorithms and AI model training platforms [3]. - The company does not pursue a "general large model" approach but focuses on specific clinical scenarios such as hematology and cytogenetics, creating a relatively vertical AI product system tailored to real application needs in laboratories and clinics [3]. Products and Technology: Advancing to Full Automation - The main commercial products include AutoVision® and MetaSight®, which have been implemented in some medical institutions [4]. - The core product, AI AutoVision®, is designed as a fully automated, end-to-end cytogenetic analysis system, aiming to elevate the current semi-automated detection to a higher level of automation [8]. Financial Performance: Rapid Revenue Growth - Deshi Biotechnology has shown continuous revenue growth, with a significant acceleration in commercialization since 2025 [9]. - Revenue data reveals: - 2023: Revenue of 52.844 million RMB - 2024: Revenue of 70.352 million RMB, a year-on-year increase of 33.1% - For the nine months ending September 30, 2025: Revenue of 111.6 million RMB, a substantial increase of 469.8% compared to 19.588 million RMB in the same period of 2024 [12]. - Sales of AutoVision® and MetaSight® increased by 40.9% and 160.0% respectively, with an increase in average selling prices due to a higher direct sales ratio [13]. Profitability Situation - The company is still in the investment phase, with R&D expenditures and sales system development impacting short-term profitability [14]. - For the nine months ending September 30, 2025, the net loss was approximately 36.6 million RMB, a reduction from 50.8 million RMB in the same period of 2024 [19]. Observations: A Vertical AI Company - Deshi Biotechnology adopts a vertical approach focused on specific testing scenarios rather than the common narrative of general medical large models [15]. - The financial structure indicates that the company has moved beyond pure R&D and is entering a phase of commercialization and revenue growth, but the sustainability of its business model will depend on the approval and large-scale implementation of its core product, AI AutoVision® [15].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has disclosed that five companies have recently obtained approval for overseas issuance and listing or full circulation of unlisted shares in China, all targeting the Hong Kong Stock Exchange and are in the process of secondary applications [1] Group 1: Company Summaries - Stone Technology, once known as a "sweeping broom" in the A-share market, saw its stock price peak at 1494.99 yuan per share in June 2021, with a market capitalization of 99.266 billion yuan, but has since decreased to a total market value of 42.361 billion yuan, representing a decline of over 50%. The company plans to issue no more than 33.108 million shares [1] - Haizhi Technology, an AI application company founded by former Baidu executives and backed by Hillhouse Capital, focuses on products like the Atlas mapping solution and Atlas intelligent agents. It intends to issue no more than 47.5846 million shares and convert 372 million shares held by shareholders into H-shares [1] - Yushi Technology specializes in L4-level autonomous driving technology, with investors including Innovation Works. The company plans to issue no more than 18.9142 million shares and convert 112 million shares held by shareholders into H-shares [1] - Deshi Biotech aims to become the first company to launch a medical imaging large model, planning to issue no more than 31.004 million shares and convert 80.88 million shares held by shareholders into H-shares [1] - Shangmi Technology, a provider of commercial IoT (BIoT) solutions with shareholders including Ant Group, Meituan, and Xiaomi, plans to issue no more than 46.004 million shares and convert 261 million shares held by shareholders into H-shares [1]

Core Viewpoint - Hangzhou Deshi Biotechnology Co., Ltd. is advancing its IPO process on the Hong Kong Stock Exchange, aiming to become the first company in the field of medical imaging large models, with significant revenue growth driven by its unique market position and favorable policies [1][2]. Group 1: Company Overview - Established in 2016, Deshi Biotechnology focuses on AI in medical imaging and smart equipment, offering a diverse product portfolio including six software products, three commercial medical devices, four main reagents and consumables, and two technology licensing products [2]. - The core product, AI AutoVision®, specializes in intelligent analysis of chromosome karyotypes, having completed clinical trials and received recognition as a Class III innovative medical device from the National Medical Products Administration [2]. Group 2: Technology and Innovation - The success of AI AutoVision® is supported by the underlying technology platform iMedImage™, which enhances product functionality and cross-scenario applications, covering 19 types of medical imaging modalities and over 90% of clinical scenarios [3]. - iMedImage™ is noted as the largest medical imaging base model globally, integrating pre-trained medical imaging technology, thus overcoming limitations of disease-specific and modality-specific small models [3]. Group 3: Market Potential - The AI medical imaging market in China is projected to grow from 2.4 billion yuan in 2024 to 40.1 billion yuan by 2030, with a compound annual growth rate of 60.2% [4]. - Policy support is evident, with the National Health Commission and other departments promoting AI medical imaging applications, aiming for widespread clinical diagnostic services in hospitals by 2030 [4]. Group 4: Funding and Future Plans - Deshi Biotechnology has secured investments from various institutions and plans to use IPO proceeds primarily for the development and commercialization of AI AutoVision®, as well as for other software and medical device R&D [4].